

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-46. Canceled.

47. (Currently Amended) A pharmaceutical composition comprising [an] a chimeric, humanized or human antibody that specifically binds to an epitope within residues 1-10 of A β and a pharmaceutical carrier.

48-66. Canceled.

67. (Currently Amended) A diagnostic kit, comprising [an] a chimeric, humanized or human antibody that specifically binds to an epitope with residues 1-10 of A β .

68. (Original) The kit of claim 67, further comprising labeling describing use of the antibody for *in vivo* diagnosis or monitoring of a disease associated with amyloid deposits of A β in the brain of a patient.

69. (Previously Presented) The pharmaceutical composition of claim 47, wherein the antibody specifically binds to an epitope within residues 1-6 of A β .

70. (Previously Presented) The pharmaceutical composition of claim 47, wherein the antibody specifically binds to an epitope within residues 1-5 of A β .

71. (Previously Presented) The pharmaceutical composition of claim 47, wherein the antibody specifically binds to an epitope within residues 1-4 of A β .

72. (New) The pharmaceutical composition of claim 47, which is a sustained release composition.

73. (New) The pharmaceutical composition of claim 47, wherein the isotype of the antibody is human IgG1.

74. (New) A pharmaceutical composition comprising an antibody that specifically binds to an epitope within A β 1-5 and a pharmaceutical carrier.

75. (New) The pharmaceutical composition of claim 74, wherein the carrier is a physiologically acceptable diluent for parenteral administration.

76. (New) The pharmaceutical composition of claim 74, wherein the pharmaceutical composition is a sustained release composition.

77. (New) The pharmaceutical composition of claim 74, wherein the isotype of the antibody is human IgG1.

78. (New) The diagnostic kit of claim 67, wherein the antibody binds to an epitope within residues 4-10 of A β .

79. (New) The diagnostic kit of claim 67, wherein the antibody binds to an epitope within residues 8-10 of A β .

80. (New) The diagnostic kit of claim 67, wherein the antibody is labelled.

81. (New) The diagnostic kit of claim 67, wherein the antibody is labelled with a paramagnetic label.

82. (New) The diagnostic kit of claim 67, wherein the labelled antibody is detected by nuclear magnetic resonance.

83. (New) The diagnostic kit of claim 67, wherein the antibody lacks capacity to induce a clearance response on binding to an amyloid deposit in the patient.

Amendments to the Drawings:

The first attached replacement drawing sheet (Figs. 1 and 2) has been amended to conform to 37 C.F.R. 1.84(l) standards for the character of lines, numbers and letters.

The second attached replacement drawing sheet (Figs. 3 and 4) has been amended to conform to 37 C.F.R. 1.84(l) standards for the character of lines, numbers and letters. Figure 4 has been further amended to replace "retrospelenial" with "retrosplenial."

The third attached replacement drawing sheet (Figs. 5 and 6) has been amended to conform to 37 C.F.R. 1.84(l) standards for the character of lines, numbers and letters.

The fourth attached replacement drawing sheet (Figs. 7 and 8) has been amended to conform to 37 C.F.R. 1.84(l) standards for the character of lines, numbers and letters.

The fifth attached replacement drawing sheet (Fig. 9) has been amended to replace "retroslpenial" with "retrosplenial."

The sixth attached replacement drawing sheet (Fig. 10) has been amended to identify the upper and lower panels of Figure 10 as Figure 10A and 10B, respectively. Figure 10 has also been amended to replace "retroslpenial" with "retrosplenial."

The seventh attached replacement drawing sheet (Figs 11 and 12) includes Fig. 11 which has been amended to include a legend.

The eighth attached replacement drawing sheet (Figs. 13 and 14) has been amended to conform to 37 C.F.R. 1.84(l) standards for the character of lines, numbers and letters.

The ninth attached replacement drawing sheet (Fig. 15A) has been amended to correct an obvious error, *i.e.*, "p Malue" has been replaced with "p Value." Support for this amendment is provided by the informal Figure 15 as originally filed in U.S. Application No.

Application No. 09/724,552
Amendment dated September 3, 2003
Reply to Office Action of June 3, 2003

09/201,430, filed November 30, 1998, which is incorporated by reference into the instant application.

The tenth attached replacement drawing sheet (Fig. 15B) has been amended to correct an obvious error, *i.e.*, "p Malue" has been replaced with "p Value." Support for this amendment is provided by the informal Figure 15 as originally filed in U.S. Application No. 09/201,430, filed November 30, 1998, which is incorporated by reference into the instant application.

The eleventh attached replacement drawing sheet (Fig. 15C) has been amended to correct an obvious error, *i.e.*, "p Malue" has been replaced with "p Value." Support for this amendment is provided by the informal Figure 15 as originally filed in U.S. Application No. 09/201,430, filed November 30, 1998, which is incorporated by reference into the instant application.

The twelfth attached replacement drawing sheet (Fig. 15D) has been amended to correct an obvious error, *i.e.*, "p Malue" has been replaced with "p Value." Figure 15D has been further amended to replace "2 μ g/ml alum" with "2 mg/ml alum." Support for these amendments is provided by the informal Figure 15 as originally filed in U.S. Application No. 09/201,430, filed November 30, 1998, which is incorporated by reference into the instant application.

The thirteenth attached replacement drawing sheet (Fig. 15E) has been amended to correct an obvious error, *i.e.*, "p Malue" has been replaced with "p Value." Support for this amendment is provided by the informal Figure 15 as originally filed in U.S. Application No. 09/201,430, filed November 30, 1998, which is incorporated by reference into the instant application.

The fourteenth attached replacement drawing sheet (Fig. 16) has been amended to orient the words in a left-to-right fashion when the page is turned so that the top becomes the left side. Figure 16 has been further amended to replace "Anti AB" with "Anti-Abeta." Support for this amendment can be found on page 92, lines 25-33 of the specification.

Application No. 09/724,552
Amendment dated September 3, 2003
Reply to Office Action of June 3, 2003

The fifteenth replacement drawing sheet (Fig. 17) has been amended to orient the words in a left-to-right fashion when the page is turned so that the top becomes the left side.

The sixteenth attached replacement drawing sheet (Fig. 18) has been amended to orient the words in a left-to-right fashion when the page is turned so that the top becomes the left side.

The seventeenth attached replacement drawing sheet (Fig. 19) been amended to delete one of the two occurrences of the sequence "VGSNKGAIIG."

The eighteenth attached replacement drawing sheet (Fig. 20) been amended to delete one of the two occurrences of the sequence "VGSNKGAIIG."

Attachment: 18 Replacement Drawing Sheets